Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Inhaled human insulin.

Thomas R Strack1

  • 1Pfizer Inc., New York, New York 10017, USA. thomas.strack@pfizer.com

Drugs of Today (Barcelona, Spain : 1998)
|May 17, 2006
PubMed
Summary
This summary is machine-generated.

Inhaled human insulin offers a noninvasive alternative for diabetes management, effectively controlling blood sugar without increasing hypoglycemia risk. It shows improved patient satisfaction compared to traditional subcutaneous insulin injections.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Inhaled insulin is associated with prolonged enhancement of glucose disposal in muscle and liver in the canine.

The Journal of pharmacology and experimental therapeutics·2008
Same author

Inhalation of human insulin (exubera) augments the efficiency of muscle glucose uptake in vivo.

Diabetes·2006
Same author

Inhalation of human insulin is associated with improved insulin action compared with subcutaneous injection and endogenous secretion in dogs.

The Journal of pharmacology and experimental therapeutics·2006
Same author

Will availability of inhaled human insulin (Exubera) improve management of type 2 diabetes? The design of the Real World trial.

Trials·2006
Same author

Inhalation of insulin (Exubera) is associated with augmented disposal of portally infused glucose in dogs.

Diabetes·2005
Same author

Inhalation of insulin in dogs: assessment of insulin levels and comparison to subcutaneous injection.

Diabetes·2004

Area of Science:

  • Endocrinology
  • Pulmonology
  • Pharmacology

Background:

  • Subcutaneous insulin therapy for diabetes is often limited by patient adherence to multiple daily injections.
  • Achieving tight glycemic control is crucial for preventing long-term diabetes complications but remains challenging.
  • An inhalable insulin presents a promising noninvasive alternative for diabetes management.

Purpose of the Study:

  • To review the clinical efficacy and safety of inhaled human insulin.
  • To evaluate its pharmacokinetic profile and glucose-lowering activity.
  • To assess patient satisfaction and safety compared to subcutaneous insulin.

Main Methods:

  • Review of current data on inhaled human insulin's clinical efficacy and safety.
  • Pharmacokinetic and glucose-lowering activity analysis.

Related Experiment Videos

  • Comparison with subcutaneous insulin therapy in type 1 and type 2 diabetes patients.

    • Main Results:

    • Inhaled human insulin mimics natural insulin secretion and rapid-acting analogs, with a rapid onset of action.
    • It effectively controls postprandial glucose and improves fasting glucose levels without increasing hypoglycemia risk.
    • The therapy shows a favorable safety profile, with reversible minor lung function reductions and increased insulin antibodies not linked to clinical issues. Patient satisfaction is higher than with subcutaneous insulin.

    Conclusions:

    • Inhaled human insulin is an effective and safe noninvasive option for managing hyperglycemia in adults with type 1 or type 2 diabetes.
    • It offers improved glycemic control and greater patient satisfaction compared to subcutaneous insulin.
    • The therapy presents a viable alternative for patients struggling with multiple daily insulin injections.